It’s time for courts to weigh in on the issue of drug pricing. As an investor, we want drug companies to earn a strong return on their investment – but using the “value of a life” thesis to justify price is too arbitrary as that might be infinite.
It’s time for courts to weigh in on the issue of drug pricing. As an investor, we want drug companies to earn a strong return on their investment – but using the “value of a life” thesis to justify price is too arbitrary as that might be infinite.